Taking this into account, UBS upgraded its Astrazeneca plc ADR [AZN] rating to a Neutral from a a Sell in a research note published recently. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who increased its forecast for the stock in early November from “a Sell” to “a Hold”. Deutsche Bank also remained covering AZN and has decreased its forecast on September 13, 2024 with a “Sell” recommendation from previously “Hold” rating. Goldman started covering the stock on May 30, 2024. It rated AZN as “a Buy”.
Price Performance Review of AZN
On Friday, Astrazeneca plc ADR [NASDAQ:AZN] saw its stock fall -0.46% to $66.60. Over the last five days, the stock has lost -0.61%. Astrazeneca plc ADR shares have risen nearly 1.65% since the year began. Nevertheless, the stocks have risen 0.53% over the past one year. While a 52-week high of $87.68 was reached on 01/17/25, a 52-week low of $60.47 was recorded on 01/14/25. SMA at 50 days reached $65.98, while 200 days put it at $74.90.
Levels Of Support And Resistance For AZN Stock
The 24-hour chart illustrates a support level at 66.20, which if violated will result in even more drops to 65.80. On the upside, there is a resistance level at 67.39. A further resistance level may holdings at 68.18. The Relative Strength Index (RSI) on the 14-day chart is 50.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.15%. Stochastics %K at 63.64% indicates the stock is a holding.
How much short interest is there in Astrazeneca plc ADR?
A steep rise in short interest was recorded in Astrazeneca plc ADR stocks on 2024-12-31, growing by 5.29 million shares to a total of 12.69 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 7.4 million shares. There was a rise of 41.69%, which implies that there is a positive sentiment for the stock.
